1432731-71-9

Basic information

• Product Name: methyl 4-(2-fluoro-4-methoxyphenyl)-7-[1-(2-methylpyrimidin-5-yl)propan-2-yl]quinoline-2-carboxylate
• Synonyms: methyl 4-(2-fluoro-4-methoxyphenyl)-7-[1-(2-methylpyrimidin-5-yl)propan-2-yl]quinoline-2-carboxylate
• CAS NO: 1432731-71-9
• Molecular Weight: 445.493
• Mol File: 1432731-71-9.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: methyl 4-(2-fluoro-4-methoxyphenyl)-7-[1-(2-methylpyrimidin-5-yl)propan-2-yl]quinoline-2-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 4-(2-fluoro-4-methoxyphenyl)-7-[1-(2-methylpyrimidin-5-yl)propan-2-yl]quinoline-2-carboxylate(1432731-71-9)
• EPA Substance Registry System: methyl 4-(2-fluoro-4-methoxyphenyl)-7-[1-(2-methylpyrimidin-5-yl)propan-2-yl]quinoline-2-carboxylate(1432731-71-9)

Safety Data

• Hazardous Substances Data: 1432731-71-9(Hazardous Substances Data)

Upstream product

• 7752-78-5 5-bromo-2-methylpyrimidine 
• 1432731-69-5 methyl 4-(2-fluoro-4-methoxyphenyl)-7-(prop-1-en-2-yl)quinoline-2-carboxylate 
• 1432731-66-2 methyl 7-chloro-4-(2-fluoro-4-methoxyphenyl)quinoline-2-carboxylate 

Downstream Products

• 1432730-88-5 4-(2-fluoro-4-methoxyphenyl)-7-[1-(2-methylpyrimidin-5-yl)propan-2-yl]quinoline-2-carboxamide 
• 1432730-86-3 4-(2-fluoro-4-methoxyphenyl)-7-[(2R)-1-(2-methylpyrimidin-5-yl)propan-2-yl]quinoline-2-carboxamide 
• 1432730-87-4 4-(2-fluoro-4-methoxyphenyl)-7-[(2S)-1-(2-methylpyrimidin-5-yl)propan-2-yl]quinoline-2-carboxamide 

Relevant articles and documents

QUINOLINE CARBOXAMIDE AND QUINOLINE CARBONITRILE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE

The present invention provides quinoline carboxamide and quinoline carbonitrile compounds of formula (I) wherein ring A, RQ, -L-, R1, n, R2, and R3 are as defined herein. The compounds of the invention are useful as non-competitive mGluR2 antagonists, or mGluR2 negative allosteric modulators (NAMs), and in methods of treating a patient (preferably a human) for diseases or disorders in which the mGluR2-NAM receptor is involved, such as Alzheimer's disease, cognitive impairment, schizophrenia and other mood disorders, pain disorders and sleep disorders, by administering to the patient a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof. The invention is also directed to pharmaceutical compositions comprising a compound of the invention, or a pharmaceutically acceptable salt thereof, (optionally in combination with one or more additional active ingredients), and a pharmaceutically acceptable carrier, and the use of the compounds and pharmaceutical compositions of the invention in the treatment of such diseases.